Literature DB >> 12748243

Gefitinib in recurrent non-small-cell lung cancer: an IDEAL trial?

David H Johnson, Carlos L Arteaga.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12748243     DOI： 10.1200/JCO.2003.04.001

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  6 in total

1.  Personalizing therapy in an epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small-cell lung cancer using PF-00299804 and trastuzumab.

Authors:  Ronan J Kelly; Corey Carter; Giuseppe Giaccone
Journal:  J Clin Oncol       Date:  2010-08-02       Impact factor: 44.544

2.  Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma.

Authors:  E Massarelli; H Lin; L E Ginsberg; H T Tran; J J Lee; J R Canales; M D Williams; G R Blumenschein; C Lu; J V Heymach; M S Kies; V Papadimitrakopoulou
Journal:  Ann Oncol       Date:  2015-05-29       Impact factor: 32.976

3.  HER2 expression as a potential marker for response to therapy targeted to the EGFR.

Authors:  D R Emlet; R Schwartz; K A Brown; A A Pollice; C A Smith; S E Shackney
Journal:  Br J Cancer       Date:  2006-04-24       Impact factor: 7.640

4.  A phase II study to determine the ability of gefitinib to reverse fluoropyrimidine resistance in metastatic colorectal cancer (the INFORM study).

Authors:  J Stebbing; M Harrison; R Glynne-Jones; J Bridgewater; D Propper
Journal:  Br J Cancer       Date:  2008-02-05       Impact factor: 7.640

5.  Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer.

Authors:  H S Parra; R Cavina; F Latteri; P A Zucali; E Campagnoli; E Morenghi; G C Grimaldi; M Roncalli; A Santoro
Journal:  Br J Cancer       Date:  2004-07-19       Impact factor: 7.640

6.  Expression of the epidermal growth factor receptor (EGFR) and the phosphorylated EGFR in invasive breast carcinomas.

Authors:  Christina Magkou; Lydia Nakopoulou; Christina Zoubouli; Kanelina Karali; Irene Theohari; Panagiotis Bakarakos; Ioanna Giannopoulou
Journal:  Breast Cancer Res       Date:  2008-06-03       Impact factor: 6.466
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.